Set Gasket Head Victor 270689 02-25840-08 Reinz Other Car & Truck Gaskets

  1. Home
  2. Set Gasket Head Victor 270689 02-25840-08 Reinz
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
Head Gasket Set Victor Reinz 02-25840-08 270689
Condition: New Weight: 0.78 lbs
Manufacturer Part Number:


L x W x H: 21.2 x 8.3 x 0.8

Victor Reinz

SubTitle: Quick shipping from multiple locations in the USA
Part Type: Engine Cylinder Head Gasket Set SKU: 02-25840-08
Part Number: 02-25840-08 Interchange Part Number: 270689

Does Not Apply

published on tue nov 09 2021

Set Gasket Head Victor 270689 02-25840-08 Reinz Other Car & Truck Gaskets

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

Set Gasket Head Victor 270689 02-25840-08 Reinz Other Car & Truck Gaskets

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.